LATS2 is a tumor suppressor gene of malignant mesothelioma

Cancer Research

Volumn 71, Issue 3, 2011, Pages 873-883

  Murakami, Hideki ^a   Mizuno, Tetsuya ^a   Taniguchi, Tetsuo ^a   Fujii, Makiko ^a   Ishiguro, Futoshi ^a   Fukui, Takayuki ^a   Akatsuka, Shinya ^a   Horio, Yoshitsugu ^a   Hida, Toyoaki ^a   Kondo, Yutaka ^a   Toyokuni, Shinya ^a   Osada, Hirotaka ^a   Sekido, Yoshitaka ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MERLIN; ONCOPROTEIN; ONCOPROTEIN YAP; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL PROLIFERATION; CHROMOSOME 13Q; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; GENE DELETION; GENE INACTIVATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC TRANSDUCTION; GROWTH INHIBITION; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDEL MUTATION; LARGE TUMOR SUPPRESSOR HOMOLOG 2 GENE; MALIGNANT MESOTHELIOMA; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

CELL CYCLE PROTEINS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CHROMOSOMES, HUMAN, PAIR 13; COMPARATIVE GENOMIC HYBRIDIZATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; MESOTHELIOMA; NEUROFIBROMIN 2; PROTEIN-SERINE-THREONINE KINASES; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 79551570342     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2164     Document Type: Article

References (45)

1. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004;28:93-174.
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
3. Yang H, Testa JR, Carbone M. Mesothelioma epidemiology, carcinogenesis, and pathogenesis. Curr Treat Options Oncol 2008;9:147-57.
4. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem 2006;98:723-34.
5. Fennell DA, Gaudino G, O'Byrne KJ, Mutti L, van Meerbeeck J. Advances in the systemic therapy of malignant pleural mesothelioma. Nat Clin Pract Oncol 2008;5:136-47. (Pubitemid 351330666)
6. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27:2081-90.
7. Sugarbaker DJ, Richards WG, Gordon GJ, Dong L, De Rienzo A, Maulik G, et al. Transcriptome sequencing of malignant pleural mesothelioma tumors. Proc Natl Acad Sci U S A 2008;105:3521-6.
8. Ivanov SV, Miller J, Lucito R, Tang C, Ivanova AV, Pei J, et al. Genomic events associated with progression of pleural malignant mesothelioma. Int J Cancer 2009;124:589-99.
9. Gray SG, Fennell DA, Mutti L, O'Byrne KJ. In arrayed ranks: array technology in the study of mesothelioma. J Thorac Oncol 2009;4:411-25.
10. Bueno R, De Rienzo A, Dong L, Gordon GJ, Hercus CF, Richards WG, et al. Second generation sequencing of the mesothelioma tumor genome. PLoS One 2010;5:e10612.
11. Sekido Y, Pass HI, Bader S, Mew DJ, Christman MF, Gazdar AF, et al. Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. Cancer Res 1995;55:1227-31.
12. Bianchi AB, Mitsunaga SI, Cheng JQ, KleinWM,Jhanwar SC, Seizinger B, et al. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 1995;92:10854-8.
13. Cheng JQ, Lee WC, Klein MA, Cheng GZ, Jhanwar SC, Testa JR. Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: evidence for a two-hit mechanism of NF2 inactivation. Genes Chromosomes Cancer 1999;24:238-42.
14. Xiao GH, Gallagher R, Shetler J, Skele K, Altomare DA, Pestell RG, et al. The NF2 tumor suppressor gene product, Merlin, inhibits cell proliferation and cell cycle progression by repressing cyclin D1 expression. Mol Cell Biol 2005;25:2384-94.
15. Poulikakos PI, Xiao GH, Gallagher R, Jablonski S, Jhanwar SC, Testa JR. Re-expression of the tumor suppressor NF2/Merlin inhibits invasiveness in mesothelioma cells and negatively regulates FAK. Oncogene 2006;25:5960-8.
16. Fleury-Feith J, Lecomte C, Renier A, Matrat M, Kheuang L, Abramowski V, et al. Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours. Oncogene 2003;22:3799-805.
17. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res 2005;65: 8090-5.
18. Jongsma J, van Montfort E, Vooijs M, Zevenhoven J, Krimpenfort P, van der Valk M, et al. A conditional mouse model for malignant mesothelioma. Cancer Cell 2008;13:261-71.
19. Thurneysen C, Opitz I, Kurtz S, Weder W, Stahel RA, Felley-Bosco E. Functional inactivation of NF2/Merlin in human mesothelioma. Lung Cancer 2009;64:140-7.
20. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma-A miRNA microarray analysis. Genes Chromosomes Cancer 2009;48:615-23.
21. Hamaratoglu F,WilleckeM,Kango-SinghM,Nolo R,HyunE,Tao C, et al. The tumour-suppressor genes NF2/Merlin and Expanded act through Hippo signalling to regulate cell proliferation and apoptosis. Nat Cell Biol 2006;8:27-36.
22. Edgar BA. From cell structure to transcription: Hippo forges a new path. Cell 2006;124:267-73.
23. Pan D. Hippo signaling in organ size control. Genes Dev 2007;21:886-97.
24. Saucedo LJ, Edgar BA. Filling out the Hippo pathway. Nat Rev Mol Cell Biol 2007;8:613-21.
25. Zhao B, Lei QY, Guan KL. The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr Opin Cell Biol 2008;20:638-46.
26. Overholtzer M, Zhang J, Smolen GA, Muir B, Li W, Sgroi DC, et al. Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci U S A 2006;103:12405-10.
27. Zender L, Spector MS, Xue W, Flemming P, Cordon-Cardo C, Silke J, et al. Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell 2006;125:1253-67.
28. Yokoyama T, Osada H, Murakami H, Tatematsu Y, Taniguchi T, Kondo Y, et al. YAP1 is involved in mesothelioma development and negatively regulated by Merlin through phosphorylation. Carcinogenesis 2008;29:2139-46.
29. Usami N, Fukui T, Kondo M, Taniguchi T, Yokoyama T, Mori S, et al. Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients. Cancer Sci 2006;97:387-94.
30. Taniguchi T, Karnan S, Fukui T, Yokoyama T, Tagawa H, Yokoi K, et al. Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32. Cancer Sci 2007;98:438-46.
31. Goto Y, Shinjo K, Kondo Y, Shen L, Toyota M, Suzuki H, et al. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma. Cancer Res 2009;69:9073-82.
32. Kawaguchi K, Murakami H, Taniguchi T, Fujii M, Kawata S, Fukui T, et al. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells. Carcinogenesis 2009;30:1097-105.
33. Tapon N, Harvey KF, Bell DW, Wahrer DC, Schiripo TA, Haber DA, et al. Salvador promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines. Cell 2002;110:467-78. (Pubitemid 35232290)
34. Scoles DR. The Merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta 2008;1785:32-54.
35. Baser ME. The distribution of constitutional and somatic mutations in the neurofibromatosis 2 gene. Hum Mutat 2006;27:297-306.
36. McClatchey AI, Giovannini M. Membrane organization and tumorigenesis - the NF2 tumor suppressor, Merlin. Genes Dev 2005;19:2265-77.
37. McClatchey AI, Fehon RG. Merlin and the ERM proteins - regulators of receptor distribution and signaling at the cell cortex. Trends Cell Biol 2009;19:198-206.
38. Li W, You L, Cooper J, Schiavon G, Pepe-Caprio A, Zhou L, et al. Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus. Cell 2010;140:477-90.
39. Seidel C, Schagdarsurengin U, Blumke K, Wurl P, Pfeifer GP, Hauptmann S, et al. Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma. Mol Carcinog 2007;46:865-71.
40. Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, et al. Yesassociated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer 2009;115:4576-85.
41. Steinhardt AA, Gayyed MF, Klein AP, Dong J, Maitra A, Pan D, et al. Expression of Yes-associated protein in common solid tumors. Hum Pathol 2008;39:1582-9.
42. Kawahara M, Hori T, Chonabayashi K, Oka T, Sudol M, Uchiyama T. Kpm/Lats2 is linked to chemosensitivity of leukemic cells through the stabilization of p73. Blood 2008;112:3856-66.
43. Strazisar M, Mlakar V, Glavac D. LATS2 tumour specific mutations and down-regulation of the gene in non-small cell carcinoma. Lung Cancer 2009;64:257-62.
44. Lopez-Lago MA, Okada T, Murillo MM, Socci N, Giancotti FG. Loss of the tumor suppressor gene NF2, encoding Merlin, constitutively activates integrin-dependent mTORC1 signaling. Mol Cell Biol 2009;29:4235-49.
45. James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, et al. NF2/Merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol 2009;29:4250-61.